BRIEF-Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc.

RNAC

0.00

June 9 (Reuters) - Cartesian Therapeutics Inc RNAC.O:

  • CARTESIAN THERAPEUTICS ANNOUNCES STRATEGIC LICENSING AGREEMENT WITH WESTGENE BIOPHARMA TO ACCELERATE THE DEVELOPMENT OF IN VIVO CAR-T PLATFORM IN AUTOIMMUNE DISEASES

  • CARTESIAN THERAPEUTICS ANNOUNCES STRATEGIC LICENSING AGREEMENT WITH WESTGENE BIOPHARMA TO ACCELERATE THE DEVELOPMENT OF IN VIVO CAR-T PLATFORM IN AUTOIMMUNE DISEASES

  • CARTESIAN THERAPEUTICS - CLINICAL TRIAL WITH DESCARTES-8 MRNA AND WESTGENE LNP IN MG TO START 2H 2026

  • CARTESIAN THERAPEUTICS - WESTGENE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS UNDER AGREEMENT

  • CARTESIAN THERAPEUTICS - CLINICAL STUDY TO INITIATE 2H 2026 WITH IN-HUMAN DATA EXPECTED 1H 2027

Source text: ID:nGNXbnwjyX

Further company coverage: RNAC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.